Biomarkers /
RAD51D
Overview
RAD51 paralog D (RAD51D) is a gene that encodes a protein that is a member of a protein complex thought to be involved in the early stage of recombinatorial DNA repair. Missense mutations, silent mutations, and nonsense mutations are observed in cancers such as colon cancer, skin cancer, and urinary tract cancer.
RAD51D is altered in 0.60% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAD51D are RAD51D Mutation (0.38%), RAD51D Amplification (0.15%), RAD51D Loss (0.09%), RAD51D Nonsense (0.04%), and RAD51D S207L (0.04%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of RAD51D in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.